Skip to content
ClinCalc Pro
Menu
Lipopeptide Antibiotic

Daptomycin (Prosthetic Joint Infections — Gram-positive)

Brand names: Cubicin

Daptomycin is a cyclic lipopeptide antibiotic used in bone and prosthetic joint infections caused by Gram-positive organisms, including meticillin-resistant staphylococci and enterococci, often on microbiology advice when other agents are unsuitable. This page covers its Gram-positive prosthetic joint infection use.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It inserts into the Gram-positive bacterial cell membrane in a calcium-dependent manner, causing rapid membrane depolarisation and loss of membrane potential that leads to concentration-dependent bactericidal killing.

Prescribing in practice

  • Daptomycin can cause myopathy and rarely rhabdomyolysis — monitor creatine kinase, ask about muscle pain or weakness, and consider stopping interacting myotoxic drugs such as statins during treatment.
  • It must not be used for pneumonia because it is inactivated by pulmonary surfactant, and it can rarely cause eosinophilic pneumonia which warrants stopping the drug.
  • Dosing is weight-based and the interval is extended in significant renal impairment; follow specialist microbiology and the SPC, as it is given by injection only.

Monitoring

Monitor creatine kinase regularly during treatment and assess renal function, with vigilance for muscle symptoms and respiratory deterioration.

Counselling the patient

  • Report muscle pain, tenderness or weakness during treatment.
  • Report new breathlessness, fever or cough, which need assessment.
  • Attend for the blood tests arranged to monitor this antibiotic.

Evidence & guidelines

Specialist bone and joint infection guidance positions daptomycin as an option for Gram-positive prosthetic joint infection, with creatine kinase monitoring recommended in the SPC.

Reference: IDSA MRSA Guidelines 2011; IDSA Prosthetic Joint Infection Guidelines 2013; SPC Cubicin; BSAC Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.